Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh BC.
Wong CI, et al. Among authors: hartono s.
J Clin Oncol. 2009 Oct 1;27(28):4718-26. doi: 10.1200/JCO.2008.21.7125. Epub 2009 Aug 31.
J Clin Oncol. 2009.
PMID: 19720910
Clinical Trial.